Drugs / MGTA-117
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05223699 | Feb 2022 → Feb 2023 | acute myeloid leukemia, myelodysplastic syndrome | Magenta Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-12-14 | Heidelberg Pharma AG | Results PR: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022 heidelberg-pharma.com ↗
Preliminary results from 15 patients across three dose-escalation cohorts showed target cell depletion in the blood and bone marrow, providing evidence of an active dose. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGTA-117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05223699 ↗ |
| Action | Deplete | “selectively deplete CD117-positive cells” NCT05223699 ↗ |
| Route | Intravenous | “MGTA-117 will be administered as an IV infusion” NCT05223699 ↗ |